By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Alexion Pharmaceuticals Inc. 

352 Knotter Drive

Cheshire  Connecticut  06410  U.S.A.
Phone: 203-272-ALXN Fax: 203-271-8198


Alexion Pharmaceuticals, Inc., is a global biopharmaceutical company focused on developing life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare and have no effective treatment options.

Our first marketed product, Soliris® (eculizumab), is the world’s first and only approved terminal complement inhibitor. Soliris is approved in more than 40 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the United States, European Union and Canada as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases that are caused by chronic uncontrolled complement activation.

Alexion currently has nine lead development programs with Soliris and four other highly innovative therapeutic candidates for patients with life-threatening and ultra-rare disorders beyond PNH and aHUS. These include, asfotase alfa as a treatment for patients with hypophosphatasia and cPMP replacement therapy for newborns with molybdenum cofactor deficiency Type A. Please click here to see our entire pipeline.

Alexion was established in New Haven, Conn. in 1992 and became a public company in 1996 (NASDAQ: ALXN). In recent years, Alexion was added to the NASDAQ-100 Index (2011) and to the Standard & Poor’s 500 Index (2012).

Headquartered in Cheshire, Conn., Alexion employs more than 1,500 people around the world. In addition to our global headquarters, Alexion's facilities include a manufacturing plant in Smithfield, R.I., a translational medicine facility in Cambridge, Mass., EMEA (Europe, Middle East & Africa) region headquarters in Lausanne, Switzerland, a European shared service center in Paris, distribution and sales operations in major markets throughout Europe, and new operations in Sydney, São Paulo, Ontario and Tokyo. The company is also expanding its reach in Latin America, the Middle East and Africa. Alexion plans to move its global headquarters back to New Haven, Conn. in 2015.

Key Statistics

Ownership: Public

Web Site: Alexion
Employees: 1,500
Symbol: ALXN



Company News
Alexion (ALXN) To Highlight Robust Rare Disease Pipeline At Investor Day 11/19/2015 10:23:10 AM
Alexion (ALXN) Release: Long-Term Follow-Up Study Presented At American Society of Nephrology 2015 Supports Effectiveness Of Soliris (Eculizumab) In Preventing Thrombotic Microangiopathy (Tma) Events In Patients With Atypical Hemolytic Uremic Syndrome (aHUS) 11/9/2015 10:51:43 AM
Alexion (ALXN) Release: Researchers to Present Data on Enhancing the Understanding of PNH and aHUS And Underscoring The Effectiveness Of Soliris (Eculizumab) Treatment At American Society of Hematology 2015 Annual Meeting 11/6/2015 11:33:43 AM
Alexion (ALXN) Reports Third Quarter 2015 Results 10/29/2015 1:16:55 PM
FDA Green Lights Alexion (ALXN)'s Metabolic Disorder Drug Strensiq 10/26/2015 7:53:34 AM
Alexion (ALXN) Release: Significant Improvements In Skeletal Mineralization And Physical Function Observed In Children With Hypophosphatasia (HPP) Treated With Strensiq (Asfotase Alfa) Sustained For At Least Five Years 10/13/2015 1:05:57 PM
Alexion (ALXN) To Report Third Quarter 2015 Results On Thursday, October 29, 2015 10/12/2015 8:24:10 AM
Alexion (ALXN) Announces Presentations At ASN 2015, Including A Long-Term Follow-Up Study Of Soliris (eculizumab) For The Prevention Of Thrombotic Microangiopathy (TMA) In Patients With Atypical Hemolytic Uremic Syndrome (aHUS) 10/5/2015 9:46:21 AM
Alexion (ALXN) Announces Presentations At 2015 American Society For Bone And Mineral Research Annual Meeting, Including New Data On Strensiq (Asfotase Alfa) In Children With Hypophosphatasia (HPP) Treated For Five Years 9/17/2015 11:06:02 AM
BioBlast Pharma (ORPN) Announces Appointment Of Tom Dubin, Former Alexion (ALXN) SVP & Chief Legal Officer, To The Board Of Directors 9/16/2015 7:20:18 AM